Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.48 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30171185 | 0.83 | EDNRA (0.63) | EDNRA | |
| SCHEMBL5529599 | 0.83 | EDNRA (0.63) | EDNRA | |
| SCHEMBL26688897 | 0.83 | EDNRA (0.63) | EDNRA | |
| SCHEMBL25084408 | 0.81 | EDNRA (0.43) | EDNRA | |
| SCHEMBL7557151 | 0.81 | EDNRA (0.64) | EDNRA | |
| SCHEMBL30637685 | 0.79 | EDNRB (0.59) | EDNRA | |
| SCHEMBL6767337 | 0.77 | EDNRA (0.76) | EDNRA | |
| SCHEMBL29281026 | 0.77 | EDNRA (0.46) | EDNRA | |
| SCHEMBL24822108 | 0.77 | EDNRA (0.46) | EDNRASLC40A1 | |
| SCHEMBL7588377 | 0.77 | EDNRA (0.45) | EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038399-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif BioSciences Inc. | 2020-02-06 | — | — | US | claimed |
| EP-3538094-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif Biosciences, Inc. (US) | 2019-09-18 | — | — | EP | claimed |
| WO-2018144086-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | MOTIF BIOSCIENCES, INC. (US) | 2018-08-09 | — | — | WO | claimed |
| US-20180133218-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | HERCULES TECHNOLOGY MANAGEMENT CO III LLC | 2018-05-17 | — | — | US | claimed |
| US-20200038399-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif BioSciences Inc. | 2020-02-06 | — | — | US | disclosed |
| EP-3538094-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | Motif Biosciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018144086-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | MOTIF BIOSCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180133218-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | HERCULES TECHNOLOGY MANAGEMENT CO III LLC | 2018-05-17 | — | — | US | disclosed |
| EP-1230224-B1 | SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1278742-B1 | CHROMENYLMETHYLPYRIMIDINEDIAMINES AS ANTIBACTERIAL AGENTS | BASILEA PHARMACEUTICA AG (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-6821980-B1 | Substituted 5-benzyl-2,4-diaminopyrimidines | BASILEA PHARMACEUTICA AG (CH) | 2004-11-23 | — | — | US | disclosed |
| US-6818649-B2 | 5-(8-ALKOXY)-2,2-SUBSTITUTED-2H-CHROMEN-6-YLMETHYL)-PYRIMIDINE-2,4 -DIAMINE DERIVATIVES USEFUL FOR TREATING INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-11-16 | — | — | US | disclosed |
| WO-1997020839-A1 | DIAMINOPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTIBACTERIAL | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-12 | — | — | WO | disclosed |
| WO-1996016046-A2 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-30 | — | — | WO | disclosed |
| US-4792557-A | 2,4-diamino-5[4-amino (or dimethylamino)-3,5-dimethoxybenzyl]pyrimidine and antibacterial composition thereof | HOFFMAN-LA ROCHE INC. (US) | 1988-12-20 | — | — | US | disclosed |
| US-4659818-A | Intermediates for benzylpyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1987-04-21 | — | — | US | disclosed |
| US-4515948-A | BACTERICIDES, SULFA DRUG POTENTIATORS | HOFFMANN-LA ROCHE INC. (US) | 1985-05-07 | — | — | US | disclosed |
| US-4251454-A | MADE FROM ANILINOMETHYLENE CHLORO-AMINO-HYDROCINNAMONITRILE | HOFFMANN-LA ROCHE INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4076810-A | Benzylpyrimidine antibacterial composition | HOFFMANN-LA ROCHE INC. (US) | 1978-02-28 | — | — | US | disclosed |
| US-4039543-A | SUBSTITUTED BY AMINE, N-RING, AMIDE, CARBAMATE, UREA | HOFFMANN-LA ROCHE INC. (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133218-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | NISCH, KIT, MGAM | EDNRA 3891/4885NFKBIA 1278/4885RELA 1634/4885 |
| US-20200038399-A1 | FORMULATIONS, METHODS, KIT, AND DOSAGE FORMS FOR TREATING BACTERIAL INFECTION | NISCH, KIT, MGAM | EDNRA 3891/4885NFKBIA 1278/4885RELA 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.